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Yasir Jamal Sepah ⇑AbstractRetinochoroidal vascular diseases are the leading causes of blindness in the developed world. They include diabetic retinopathy
(DR), retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration (AMD), and pathological myopia,
among many others. Several different therapies are currently under consideration for the aforementioned disorders. In the
following section, agents targeting platelet-derived growth factor (PDGF) are discussed as a potential therapeutic option for
retinochoroidal vascular diseases. PDGF plays an important role in the angiogenesis cascade that is activated in retinochoroidal
vascular diseases. The mechanism of action, side effects, efficacy, and the potential synergistic role of these agents in combination
with other treatment options is discussed. The future of treatment of retinochoroidal vascular diseases, particularly AMD, has
become more exciting due to agents such as PDGF antagonists.
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Platelet-derived growth factor (PDGF) was first isolated
from platelet extracts in the early 1970s and classified as a
mitogen for fibroblasts and cells of mesenchymal origin.1
The a granules of platelets are known to be a major storage
site for PDGF; however, recent studies have also shown pres-
ence of PDGF in several other cell types. Mice studies have
highlighted the essential role of PDGF in the early develop-
ment of the embryo, with a deficiency resulting in defective
formation of the lungs, vessels, placenta, brain, and skeleton.
In these organs, cell types such as mesangial cells, pericytes,
fibroblasts, and glial cells were shown to be dependent on
PDGF.2The PDGF family consists of four ligands: A, B, C and D.
They function as homodimers with the exception of ligand
‘‘AB’’, which acts as a heterodimer.3 All four PDGF ligands
bind two structurally related tyrosine kinase cell surface
receptors, a and b,4 which relay the message internally and
initiate signal induction via Ras and phosphatidylinositol-II
pathways. These pathways are essential for PDGF-induced
cell migration and mitogenesis, respectively.5 PDGF-AA, -
AB, -BB and -CC activate the PDGF receptor-a (PDGFRa)
while PDGF-BB and -DD bind to PDGFRb (Fig. 1). PDGF-A
is expressed by neurons and astrocytes6 and, together with
PDGFRa, is responsible for recruitment and subsequent
development of astrocyte precursors in the retina.6,7 PDGF-C
plays a critical role in neuronal survival and prevention frome:
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Figure 1. Flowchart demonstrating the PDGF ligand–receptor interaction.
288 M.A. Sadiq et al.apoptosis via regulation of expression of the glycogen synthase
kinase 3b.8 In animal models, eyes treated with PDGF showed
decreased retinal pigment epithelial and photoreceptor degen-
eration.9 Pericytes express PDGFRb, allowing PDGF-BB and
PDGFRb to play an important role in the maintenance of retinal
vasculature.10,11
PDGF over-activity has also been linked with several
systemic conditions including autocrine stimulation of various
cells in tumors, atherosclerosis, and fibrotic conditions such
as lung, liver, and kidney fibrosis.12 In fact, PDGF antagonists
are currently being evaluated for the treatment of pulmonary
hypertension 13 and several different tumors.14–16
Methodology
A systematic search of literature was conducted on
PubMed, Scopus, and Google Scholar with no limitation on
language or year of publication. Words searched included
PDGF, Platelet Derived Growth Factor, PDGF AND antago-
nist, PDGF AND retinal diseases, PDGF AND AMD, PDGF
AND DME, PDGF AND retinal vascular diseases.
PDGF and retinochoroidal vascular diseases
A common feature of most retinochoroidal diseases is
some degree of vascular insult that leads to ischemia. SuchFigure 2. Flowchart depicting the various stepinjury consequently leads to release of a wide range of factors
that alter the course of the disease process. It was first pos-
tulated in 1948 that an angiogenic factor was responsible
for retinal neovascularization (NV).17 Since then, several other
key factors have been identified for their critical role in the
disease process. Hypoxia inducible factor-1 (HIF-1) was
identified as a transcription factor that mediates increased
expression of several genes associated with NV. These genes
lead to the increased transcription of several key factors that
are eventually responsible for new vessel formation; these
include vascular endothelial growth factor (VEGF), PDGF,
stromal derived growth factor-1 (SDF-1), and placental
growth factor (PIGF).
Angiogenesis is considered to consist of five basic steps
(Fig. 2) that include degradation of basement membranes,
migration of endothelial cells, tube formation by endothelial
cells, new basement membrane formation and finally,
encirclement by pericytes for stabilization. In-vitro studies
have demonstrated the role of PDGF in the angiogenesis
process.18 It has been shown to promote migration and
proliferation of endothelial cells along with an increase in the
recruitment of pericytes. These findings, therefore, suggest
that PDGF plays a key role in the angiogenesis cascade.
High glucose levels have been shown in-vitro to lead to
increased expression of PDGF-b, and therefore, an increase
in its binding to PDGF-BB.19 This glucose-related increaseds involved in the pathway of angiogenesis.
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Platelet derived growth factor inhibitors 289expression was seen in mesangial cells, endothelial cells, and
macrophages. Mice studies have shown that retina-specific
expression of PDGF-B leads to severe NV and retinal detach-
ment.20 Similar migratory and proliferative effects of PDGF
have also been documented in rabbits.21 A study conducted
by Freyberger et al. reported that PDGF levels were raised in
both diabetic and non-diabetic proliferative retinopathy.22
According to Robbins et al, PDGF-A staining was limited to
vessels in the normal retina and choroid, whereas in the
diseased retina and choroid, the staining was widespread in
the cytoplasm of cells such as macrophages, RPE cells, and
fibroblast-like cells. Similarly, unlike normal RPE cells, RPE
cells within NV membranes stained strongly positive for
PDGF-B receptors, suggesting increased concentrations of
both ligands and receptors in such conditions.23 Therefore,
it might be postulated that PDGF, together with other
growth factors, plays an integral part in the NV process found
in diabetic eyes.
One possible explanation for the involvement of PDGF in
the NV process includes entry of platelets and monocytes
into the vitreous and subretinal space upon injury to the
blood-retina barrier, with subsequent platelet aggregation
and PDGF discharge. Interleukins such as IL-1 and TGF-B,
released from activated macrophages may lead to further
synthesis of PDGF.Ta
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retinochoroidal vascular diseases
Several treatment strategies for retinochoroidal vascular
diseases have been aimed at blocking the effects of PDGF
in the angiogenesis process.
In a mice study, Dong et al. tested the effect of a designed
ankyrin repeat protein (DARPin) that selectively binds to and
antagonizes PDGF-BB in subretinal NV; the effect was
compared to a similar protein that antagonized VEGF-A.
According to the study, intra-peritoneal injection of 10 mg/kg
of the anti-PDGF protein or 1 mg/kg of the anti-VEGF protein
significantly suppressed subretinal NV.24 The effect of
injection of 1 mg/kg anti PDGF-DARPin was not significant;
however, when combined with 1 mg/kg anti-VEGF-A DARPin,
the suppression was greater than that achieved by the
anti-VEGF-DARPin alone. Similarly, strong suppression of
retinal NV was also achieved with 1.85 lg of anti-PDGF-BB
DARPin. These findings suggest that PDGF is a valid target
for the treatment of ocular NV.
Several clinical trials evaluating the role of PDGF antago-
nists in human eyes are currently ongoing (Table 1). These
studies are looking at the safety profile of the available
PDGF antagonists as well as their efficacy in comparison with
and in combination with other currently available VEGF
antagonists.
Ophthotech (New York, U.S.A.) developed a high affinity
PDGF antagonist called E10030. This molecule binds to
PDGF and blocks its binding to PDGFR-b. In-vitro/in-vivo
studies using this compound have shown the effectiveness
of its combination with an anti-VEGF agent in preventing
the formation of CNV, as well as in the stripping of pericytes
from vessels that have already formed, leading to their
regression. A phase-I clinical trial that investigates the safety
and tolerability of E10030 in humans in combination with
ranibizumab or as a monotherapy has been completed.25 A
290 M.A. Sadiq et al.dose-escalation (0.03 mg, 0.3 mg, 1.5 mg and 3.0 mg)
scheme was used. All dose levels were well tolerated with
no dose-related toxicities being reported. A significant visual
gain (increase in BCVA of P15 letters) was seen in 59% of
patients at week 12. Central retinal thickness (CRT), detected
by optical coherence tomography (OCT) showed a decrease
in thickness at all study visits for all treatment groups. The
mean CRT was 395 lm at baseline, 251 lm at week 4,
231 lm at week 8, and 229 lm at week 12. Fluorescein
angiography (FA) also demonstrated neovascular regression
in all patients from baseline to week 12, with the mean
decrease in CNV size being 85.5% compared to baseline.
In conclusion, E10030 showed potential as a possible
future therapeutic agent when used in combination with
ranibizumab.26 Following the results of the phase-I study, a
phase-II, randomized, double-blind clinical trial was initiated
to further evaluate E10030.27 The study enrolled 449 patients
who were randomized in a 1:1:1 ratio into the following
groups: 0.3 mg anti-PDGF with 0.5 mg ranibizumab, 1.5 mg
anti-PDGF with 0.5 mg ranibizumab, and a sham injection
given in conjunction with ranibizumab 0.5 mg. The primary
outcome measure of the study was change in BCVA from
baseline to week 24. The study results reported that combi-
nation therapy of anti-PDGF and ranibizumab was superior
to ranibizumab alone, with the combination arm showing
62% improvement in vision. Mean improvement in BCVA
was: 10.6 letters, 8.74 letters and 6.52 letters in the 1.5 mg
combination group, 0.3 mg combination group and the
ranibizumab monotherapy group respectively (P = 0.019 for
ranibizumab only in comparison with each combination
group). The BCVA outcomes in the combination groups were
also superior to the monotherapy group when the patients
were separately assessed after being subdivided into
two groups based on their baseline CRT (CRT < 316 lm or
CRT > 480 lm).28
A phase-III, randomized, double-blind clinical trial has
recently been initiated for E10030.29 The study aims to enroll
622 patients. It will compare the effect of 1.5 mg E10030
intravitreal injection + 0.5 mg ranibizumab intravitreal injec-
tion to E10030 sham intravitreal injection + ranibizumab
0.5 mg intravitreal injection. The primary outcome measure
of the study is the mean change in BCVA from baseline to
month 12. Another similar phase-III study has been initiated
that plans to compare the combination therapy of E10030
with that of aflibercept or bevacizumab. This study is
currently not recruiting.30 Table 1 provides a summary of
these trials.Summary and conclusion
Anti-VEGF monotherapy, has no doubt, proven to be
effective in the treatment of AMD. However, the outcomes
of patients receiving anti-VEGF therapy has fallen short of
expectations for two-thirds of the patients in most clinical
trials. Similarly, the long term effects of anti-VEGF therapy
have also come under scrutiny in recent times. According
to the SEVEN-UP study (Seven-year outcomes in ranibizumab-
treated patients in ANCHOR, MARINA, and HORIZON: a
multicenter cohort), at a mean of 7.3 years after entering the
ANCHOR or MARINA trial, BCVA in 34% of study eyes
declined by 15 letters or more, with an overall mean decline
of 8.6 letters (P < 0.005). Similar limitations in the long termoutcomes of patients were also seen in the comparison of
AMD treatment trials (CATT) study.31
By blocking pericyte’s recruitment, survival and maturation,
PDGF antagonists inhibit the development and maturation
of newly formed vessels, thereby, offering an exciting new
treatment option for patients with neovascular AMD.
Recent trials comparing the benefit of combination ther-
apy of ranibizumab and PDGF antagonists to ranibizumab
monotherapy have shown superiority of the combination
therapy. This might be explained by the fact that both
VEGF and PDGF levels increase in neovascularization, and
the VEGF is neutralized by anti-VEGF but PDGF continues
to work in the absence of PDGF antagonists. In fact, chronic
anti-VEGF treatment causes PDGF upregulation, leading to
pericyte recruitment and neovascular membrane stabiliza-
tion.32 By using PDGF antagonists in combination with
VEGF, this vessel protective mechanism may be surpassed
to provide a therapeutic option, which treats neovasculariza-
tion in a more effective manner.
Although PDGF antagonists might have a potential role
for treatment in AMD, their role in the treatment of DR might
be limited due to the fact that PDGF is required for pericyte
retention and recruitment.33
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